Inhibition of PKC-βII for Chemoprevention
Posted by WH in News, tags: chemoprevention, oncology
Inappropriate activation of PKC isozymes has been implicated in many forms of cancer and researchers at the Mayo Clinic, Florida Campus, have been elucidating the roles of the isozymes in colon carcinoma using transgenic mice. Their earlier studies, reported in the January 15th issue of Cancer Research, demonstrated a requirement for PKC-βII in the initiation of colon cancer in mice exposed to a carcinogen. The same study also showed that PKC-ι/λ was required for cancer progression.
Now the scientists have shown that daily administration of the selective PKC-β inhibitor, Enzastaurin, provides a degree of protection to mice administered a carcinogen known to cause colon tumours. Since colon cancer develops over a 10-15 year period in humans, there is a large window of opportunity for the use of chemopreventative drugs. The authors suggest that Enzastaurin could represent a good candidate for clinical study in this setting because it has few side-effects.
Enzastaurin is currently in Phase III clinical trials for the treatment of B-cell lymphoma and high-grade brain gliomas. Although Enzastaurin is selective for PKC-β, it also significantly inhibits other PKC isozymes.
The full study with Enzastaurin is published in the February 15th issue of Cancer Research.
Related posts:
- Intestinal Flora may Trigger Colon Cancer Just as Helicobacter pylori, which causes stomach ulcers and gastric cancers, is being eradicated from many developed countries, Johns Hopkins...
- More Benefits of ACE Inhibition and Angiotensin Receptor Blockade Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs) were developed primarily to treat hypertension, but several recent studies...
- Liquorice Does Allsorts Liquorice, which is used as a traditional medicine, a culinary spice and an ingredient of confectionary, is an expectorant and...
- Rheb is Overexpressed in Certain Cancers The mTOR (mammalian target of rapamycin) pathway represents a convergence point for signalling pathways commonly disrupted in cancer. The pathway...
- Targeting Cancer Stem Cells Cancer stem cells are slowly dividing tumourigenic cells that possess characteristics of normal stem cells. It has been proposed that...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Friday, February 20th, 2009 at 8:30 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Entries (RSS)